"10.1371_journal.pone.0065189","plos one","2013-05-28T00:00:00Z","Julie Steinestel; Marcus V Cronauer; Johannes Müller; Andreas Al Ghazal; Peter Skowronek; Annette Arndt; Klaus Kraft; Mark Schrader; Andres J Schrader; Konrad Steinestel","Department of Urology, University of Ulm, Ulm, Germany; Gemeinschaftspraxis for Pathology Augsburg, Augsburg, Germany; Institute of Pathology and Molecular Pathology, Bundeswehrkrankenhaus Ulm, Ulm, Germany; Bundeswehr Institute of Radiobiology, Munich, Germany; Institute of Pathology, University of Ulm, Ulm, Germany","Conceived and designed the experiments: JS AS KS. Performed the experiments: JS JM AAG PS AA KS. Analyzed the data: JS MC PS AA KK KS. Contributed reagents/materials/analysis tools: MC AA AS MS KK. Wrote the paper: JS AS KS.","The authors read the journals policy and have the following conflicts: Prof. AJ Schrader receives compensation as a consultant for Bayer Healthcare AG, which manufactures Sorafenib (Nexavar®) for clinical application. All other authors have declared that no competing interests exist. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2013","05","Julie Steinestel","JS",10,FALSE,3,6,6,3,TRUE,TRUE,FALSE,0,NA,FALSE
